Hepatitis delta is a public health concern in the community setting: The role of prison health care units in limiting the spread of infection in general population

Journal title MISSION
Author/s Felice Alfonso Nava, Giulia Bassetti, Marco Cristofoletti, Massimo Fornaini, Raffaele Geraci, Marina Paties, Carlo Poggi, Stefano Tolio, Claudio Pilerci
Publishing Year 2022 Issue 2020/56
Language English Pages 4 P. 43-46 File size 0 KB
DOI 10.3280/mis56-2020oa12975
DOI is like a bar code for intellectual property: to have more infomation click here

View article Download Open Access article

FrancoAngeli is member of Publishers International Linking Association, Inc (PILA), a not-for-profit association which run the CrossRef service enabling links to and from online scholarly content.

Hepatitis D virus (HDV) is a public health concern for its severe medical consequences. The aim of this pilot study was to evaluate the prevalence of the main infectious disease between the detainees of the Veneto Region. The study consisted of a survey carried between the heads of the prison healthcare staff. The data showed that on 2,119 detainees the prevalence of hepatitis B (HBV) is the 6% and that the most relevant prevalence of HBV was revealed in the East Europe detainees (Ex USSR countries, Albania, Bosnia, Kosovo, Macedonia), being the 39% of all HBcAb positive subjects. The survey also revealed as the population less protected by HVB vaccination was that comes from East Europe. Moreover, the study indicates that hepatitis D diagnosis is not well known by clinician working inside prisons and that it should be improved through specific diagnostic and therapeutic procedures. Our data indicate that the prison setting may play an important and crucial role in term of public health both in intercepting patients that need of treatment and in preventing actions able to minimize the risk of infection. In prison settings screening, linkage to care and harm reduction measures should be improved in order to protect the general population from the impact of the emerging infectious diseases, including HDV.

Keywords: Hepatitis D virus (HDV), Hepatitis B virus (HBV), Prison, Harm reduction

  1. Botelho-Souza L.F., Vasconcelos M.P.A., Dos Santos A.O., Salcedo JM.V., Vierira D.S. (2017). Hepatitis delta: virological and clinical aspects. Virol. J., 14: 177.
  2. Caviglia G.P., Rizzetto M. (2020). Treatment of hepatitis D: an unmet medical need. Clin. Microbiol. Infect., 26: 824-827.
  3. Chen F., Zhang J., Guo F., Wen B., Luo S., Yuan D., Lin Y., Ou W., Tang P., Dai G., Li F., Liu W., Qu X. (2017). Hepatitis B, C, and D virus infection showing distinct patterns between injection drug users anf the general population. J. Gastroenterol. Hepathol., 32: 515-520.
  4. Chen H.Y., Shen D.T., Ji D.Z., Han P.C., Zhang W.M., Ma J.F., Chen W.S., Goyal H., Pan S., Xu H.G. (2019). Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut, 68: 512-521.
  5. Hercun J., Koh C., Heller T. (2020). Hepatitis delta: prevalence, natural history, and treatment options. Gastroenterol. Clin North Am., 49: 239-252.
  6. Fazel S., Baillargeon J. (2011). The health of prisoners. Lancet, 377: 956-965.
  7. Gaeta G.B., Strofoflini T., Chiaramonte M., Ascione T., Stornaiuolo G., Lobello S., Sagnelli E., Brunetto M.R., Rizzetto M. (2000). Chronic hepatitis D: a vanishing disease? Hepathology, 32: 824-827.
  8. Gheorghe L.,, csiki I.E., Iacob S., Gheorghe C., Trifan A., Grigorescu M., Motoc A., Suceveanu A., Curescu M., Caruntu F., Sporea I., Brisc C., Rogoveanu I., Cerban R., Tugui L., Alexandrescu A. (2015). Hepatitis delta virus infection in romania: prevalence and risk factors. J. Gastrointestin. Liver Dis., 24: 413-421.
  9. Gilman C., Heller T., Koh C. (2019). Chronic hepatitis delta: a state of the art review and new therapies. World J. Gastroenterol., 25: 4580-4597.
  10. Grigolin V., De Mari M., Dinelli E., Marcolongo L., Montalto S., Padovan G.B., Pojano G., Zorzi F., Orcamo P., Nava F.A. (2021). Prison health is a public health, management of Sars-CoV-“ outbreak in an Italian prison. Mission – Italian Quarterly Journal of Addiction, 55: 32-35.
  11. Kushner T., Serper M., Kaplan D.E. (2015). Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factor, and outcomes. J. Hepathol., 63: 586-592.
  12. Lempp F.A., Ni Y., Urban S. (2016). Hepatitis delta virus: insight into a peculiar pathogen and novel treatment opitions. Nat. Rev. Gastroenterol. Hepathol., 13: 580-589.
  13. Lin H.H., Lee S.S., Yu M.L., Chang T.T., Su c.W., Hu B.S., Chen Y.S., Huang C.K., Lai C.H., Lin J.N., Wu J.C. (2015). Changing hepatitis D virus epidemiology in a hepatitits B virus endemic area with a national vaccination program. Hepatology, 61: 1870-1879.
  14. Mahale P., Aka P.V., Chen X., Liu P., Wang A.S., Simenel S., Tseng F.C., Chen S., Edlin B.R., Glenn J.S., O’Brien T.R. (2018). Heptitis D viremi among injection drug users in San Francisco. J. Infect. Dis., 217: 1902-1906.
  15. Mentha N., Clement S., Negro F., Alfaiate D. (2019). A review on hepatitis D: from virology to new therapies. J. Adv. Res., 17: 3-15.
  16. Niro G.A., Ferro A., Cicerchia F., Brascugli I., Durazzo M. (2021). Hepatitis delta virus: from infection to new therapeutic strategies. Word J. Gastroenterol., 27(24): 3350-3542.
  17. Opitz-Welke A., Lehmann M., Seidel P., Konrad N. (2018). Medicine in the penal system. Dtsch Arztebl Int., 115: 808-814.
  18. Perez-Vargas J., Amirache F., Boson B., Mialo C., Freitas N., Sureau C., Fusil F., Cosset F.L. (2019). Enveloped viruses distinct from HBV induce dissemination of hetaptis D virus in vivo. Nat. Commun., 10: 2098.
  19. Rizzetto M. (2016). The adventure of delta. Liver Int., 36 Suppl. 1: 135-140.
  20. Rizzetto M., Alavian S.M. (2013). Hepatitis delta: the rediscovery. Clin. Liver Dis., 17: 475-487.
  21. Shih H.H., Jeng K.S., Syu W.J.m Huang Y.H., Su C.W., Peng W.L., Sheen I.J., Wu J.C., 2008. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J. Virol., 82: 2250-2264.
  22. Simpson P.L., Simpson M., Adily A. Grant L., Butler T. (2019). Prison cell spatial density and infectious and communicable diseses: a systematic review. BMJ Open., 9(7): e026806.
  23. Stockdale A.J., Kreuels B., Henrion M.Y.R., Giorgi E., Kyomuhangi I., de Martel C., Hutin Y., Geretti A.M. (2020). The global prevalence of hepatitits D virus infection: systematic review and meta-analysis. J. Hepathol., 73: 523-532.
  24. Sureau C., Negro (2016). The hepatitis delta virus: replication and pathogenesis. J. Hepathol., 64: S102-S116.
  25. Taylor J., Pricell R.H., Farci P. (2013). Hepatitis D (delta virus). In: Knipe D.M., Howley P.M., Fields virology. Philadelphia: Lippincott, Williams ad Wilkins, 2222-2241.

  • The HBV/HDV screening and linkage to care in drug users: A therapeutic diagnostic pathway (PDTA) Felice Alfonso Nava, Loreta A. Kondili, in MISSION 63/2024 pp.18
    DOI: 10.3280/mis63-64-2023oa17586
  • Infection diseases in the prisons: A public health warming. Priority action to protect general community Felice Alfonso Nava, Loreta Kondili, Lucia Craxi, Valentina Grigolin, Annamaria Cattelan, Francesco Paolo Russo, Alfredo Alberti, in MISSION 57/2022 pp.18
    DOI: 10.3280/mis57-2022oa14304

Felice Alfonso Nava, Giulia Bassetti, Marco Cristofoletti, Massimo Fornaini, Raffaele Geraci, Marina Paties, Carlo Poggi, Stefano Tolio, Claudio Pilerci, Hepatitis delta is a public health concern in the community setting: The role of prison health care units in limiting the spread of infection in general population in "MISSION" 56/2020, pp 43-46, DOI: 10.3280/mis56-2020oa12975